BR0208120A - Insulina modificada com imunogenicidade reduzida - Google Patents
Insulina modificada com imunogenicidade reduzidaInfo
- Publication number
- BR0208120A BR0208120A BR0208120-2A BR0208120A BR0208120A BR 0208120 A BR0208120 A BR 0208120A BR 0208120 A BR0208120 A BR 0208120A BR 0208120 A BR0208120 A BR 0208120A
- Authority
- BR
- Brazil
- Prior art keywords
- insulin
- polypeptides
- reduced immunogenicity
- modified
- modified insulin
- Prior art date
Links
- 230000005847 immunogenicity Effects 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 230000002163 immunogen Effects 0.000 abstract 2
- 230000004048 modification Effects 0.000 abstract 2
- 238000012986 modification Methods 0.000 abstract 2
- 241000282412 Homo Species 0.000 abstract 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
"INSULINA MODIFICADA COM IMUNOGENICIDADE REDUZIDA". A presente invenção refere-se a polipeptídeos a serem administrados especialmente a seres humanos em particular para uso terapêutico. Os polipeptídeos são polipeptídeos modificados pelo que a modificação resulta em um tendência reduzida do polipeptídeo para eliciar uma resposta imune quando da administração ao indivíduo humano. A invenção em particular refere-se à modificação de insulina humana para resultar em proteínas de insulina que são substancialmente não-imunogenicas ou menos imunogênicas do que qualquer correspondente não-modificado quando usado in vivo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01106900 | 2001-03-20 | ||
| PCT/EP2002/003015 WO2002074808A2 (en) | 2001-03-20 | 2002-03-19 | Modified insulin with reduced immunogenicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0208120A true BR0208120A (pt) | 2004-03-09 |
Family
ID=8176848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0208120-2A BR0208120A (pt) | 2001-03-20 | 2002-03-19 | Insulina modificada com imunogenicidade reduzida |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20040096459A1 (pt) |
| EP (1) | EP1412385A2 (pt) |
| JP (1) | JP2004533817A (pt) |
| KR (1) | KR20030085007A (pt) |
| CN (1) | CN1524090A (pt) |
| BR (1) | BR0208120A (pt) |
| CA (1) | CA2441388A1 (pt) |
| HU (1) | HUP0303523A3 (pt) |
| MX (1) | MXPA03008402A (pt) |
| PL (1) | PL369309A1 (pt) |
| RU (1) | RU2003130060A (pt) |
| WO (1) | WO2002074808A2 (pt) |
| ZA (1) | ZA200308061B (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006007667A1 (en) * | 2004-07-23 | 2006-01-26 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic and diagnostic agents |
| US20090271021A1 (en) * | 2008-04-28 | 2009-10-29 | Popp Shane M | Execution system for the monitoring and execution of insulin manufacture |
| EP3595694A4 (en) * | 2017-03-14 | 2021-06-09 | The Regents of The University of California | CONSTRUCTION OF CAS9 CRISPR IMMUNE FURTIF |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5514646A (en) * | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| AU736549B2 (en) * | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
| GB9712892D0 (en) * | 1997-06-20 | 1997-08-20 | Eclagen Ltd | Identification of mhc binding peptides |
| CA2342967A1 (en) * | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
-
2002
- 2002-03-19 CN CNA028062620A patent/CN1524090A/zh active Pending
- 2002-03-19 KR KR10-2003-7012145A patent/KR20030085007A/ko not_active Application Discontinuation
- 2002-03-19 US US10/473,633 patent/US20040096459A1/en not_active Abandoned
- 2002-03-19 RU RU2003130060/04A patent/RU2003130060A/ru not_active Application Discontinuation
- 2002-03-19 BR BR0208120-2A patent/BR0208120A/pt not_active IP Right Cessation
- 2002-03-19 HU HU0303523A patent/HUP0303523A3/hu unknown
- 2002-03-19 JP JP2002573815A patent/JP2004533817A/ja active Pending
- 2002-03-19 WO PCT/EP2002/003015 patent/WO2002074808A2/en not_active Application Discontinuation
- 2002-03-19 EP EP02726186A patent/EP1412385A2/en not_active Withdrawn
- 2002-03-19 MX MXPA03008402A patent/MXPA03008402A/es unknown
- 2002-03-19 PL PL02369309A patent/PL369309A1/xx unknown
- 2002-03-19 CA CA002441388A patent/CA2441388A1/en not_active Abandoned
-
2003
- 2003-10-16 ZA ZA200308061A patent/ZA200308061B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002074808A3 (en) | 2004-02-26 |
| RU2003130060A (ru) | 2005-04-10 |
| WO2002074808A2 (en) | 2002-09-26 |
| CA2441388A1 (en) | 2002-09-26 |
| HUP0303523A2 (hu) | 2004-01-28 |
| HUP0303523A3 (en) | 2005-12-28 |
| CN1524090A (zh) | 2004-08-25 |
| EP1412385A2 (en) | 2004-04-28 |
| PL369309A1 (en) | 2005-04-18 |
| MXPA03008402A (es) | 2004-01-29 |
| ZA200308061B (en) | 2004-07-14 |
| US20040096459A1 (en) | 2004-05-20 |
| KR20030085007A (ko) | 2003-11-01 |
| JP2004533817A (ja) | 2004-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0207016A (pt) | Fator neurotrófico derivado de cérebro humano modificado (bdnf) com imunogenicidade reduzida | |
| BR0208041A (pt) | Interferon beta modificado com imunogenicidade reduzida | |
| BR0207283A (pt) | Anticorpos anti-egfr modificados com imunogenicidade reduzida | |
| DK395689D0 (da) | Pharmaceutisk tilberedning til behandling af diabetes mellitus | |
| BR0207018A (pt) | Leptina modificada com imunogenicidade reduzida | |
| BR9814473A (pt) | Imunógenos anti-retrovirais, preparação e uso | |
| BR0207704A (pt) | Alfa interferon modificado com imunogenicidade reduzida | |
| BR0207015A (pt) | Eritropoientina modificada (epo) com imunogenicidade reduzida | |
| BR0207014A (pt) | Antagonista de receptor de interleucina-1 modificada (il-1ra) com imunogenicidade reduzida. | |
| BR0207905A (pt) | Protamina modificada com imunogenicidade reduzida | |
| BR0207705A (pt) | Fator neurotrófico ciliar modificado (cntf) com imonogenicidade reduzida | |
| BR0207945A (pt) | Fator estimulante de colÈnia de macrófagos granulócitos modificados (gm-csf) com reduzida imunogenicidade | |
| BR0207542A (pt) | Trombopoietina modificada com imunogenicidade reduzida | |
| BR0211091A (pt) | Métodos para redução de imunogenicidade de polipeptìdeos | |
| BR0207017A (pt) | Fator de crescimento ceratinócito modificado (kgf) com imunogenicidade reduzida | |
| BR0208120A (pt) | Insulina modificada com imunogenicidade reduzida | |
| BR0207020A (pt) | Fator de estimulação de colÈnia por granulócito (g-csf) modificado com imunogenicidade reduzida | |
| BR0211991A (pt) | HormÈnio do crescimento humano modificado | |
| BR0214567A (pt) | Epìtopos de célula t em carboxipeptidase g2 | |
| ES2183376T3 (es) | Uso de lbp para el tratamiento de la septicemia. | |
| BR0213554A (pt) | Timosina para aumento da imunização genética | |
| BRPI0405862A (pt) | composição vacinal contra linfadenite |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A,6A E 7A ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009. |